Last reviewed · How we verify
Beyfortus
At a glance
| Generic name | Beyfortus |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Target | Fusion glycoprotein F0 |
| Modality | Biologic |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease
Common side effects
- Rash
- Injection site reactions
Key clinical trials
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (PHASE4)
- Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India (PHASE4)
- Safety of RSV Preventive Monoclonal Antibody (PHASE4)
- Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants
- Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV
- A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
- BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
- Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beyfortus CI brief — competitive landscape report
- Beyfortus updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI